Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: kidney
- Who it enrolls
- age 18 Years to 80 Years; excludes diabetes; no BMI minimum stated; conditions: Type 2 Diabetic Nephropathy
- Interventions
- Dulaglutide Injection
- Conditions
- Type 2 Diabetic Nephropathy
- Phase and size
- NA · 300 participants
- Dates
- Start 2021-10-30
Primary completion 2023-06-30 - Sponsor
- The Affiliated Hospital of Xuzhou Medical University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Evaluation of the urinary albumin-to-creatinine ratio3,6 and 12 months after dulaglutide injection treatment
- Evaluation of the biomarkers of the epithelial-mesenchymal transition process3,6 and 12 months after dulaglutide injection treatment
02Eligibility
Who can take part
Inclusion Criteria: * All adults aged 18 and above * No minors involved in the study * Diabetic Nephropathy defined as a urinary albumin-to-creatinine ratio ≥30 mg/g at least twice in three measurements within a period of 3-6 months Exclusion Criteria: * Patients with other types of kidney disease * Urinary tract infection * Type 1 diabetes
03Change log
Registry changes
No changes recorded since the trial was added.